Immunoregulatory properties of the cytokine IL-34
Open accessAbstract
Interleukin-34 is a cytokine with only partially understood functions, described for the first time in 2008. Although IL-34 shares very little homology with CSF-1 (CSF1, M-CSF), they share a common receptor CSF-1R (CSF-1R) and IL-34 has also two distinct receptors (PTP-ζ) and CD138 (syndecan-1). To make the situation more complex, IL-34 has also been shown as pairing with CSF-1 to form a heterodimer. Until now, studies have demonstrated that this cytokine is released by some tissues that differ to those where CSF-1 is expressed and is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Our recent work has demonstrated a new and possible therapeutic role for IL-34 as a Foxp3 + Treg-secreted cytokine mediator of transplant tolerance. In this review, we recapitulate most recent findings on IL-34 and its controversial effects on immune responses and address its immunoregulatory properties and the potential of targeting this cytokine in human.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IL-34 produced by osteoblasts recognizes the receptor for M-CSF (C-Fms) on osteoclast progenitors, thereby promoting osteoclastogenesis.
“IL-34 produced by osteoblasts recognizes the receptor for M-CSF (C-Fms) on osteoclast progenitors, thereby promoting osteoclastogenesis [38].”
From Osteoclasts and Microgravity (2020) · cites this paper as [38]
Cites
Dai, X.-M., Ryan, G. R., Hapel, A. J., Dominguez, M. G., Russell, R. G., Kapp, S., Sylvestre, V., & Stanley, E. R. (2002) · Blood · doi:10.1182/blood.v99.1.111 · Cited by 1,184 · see citing works
Greter, M., Lelios, I., Pelczar, P., Hoeffel, G., Price, J., Leboeuf, M., Kündig, T. M., Frei, K., Ginhoux, F., Merad, M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.11.001 · Cited by 630 · see citing works
Mizuno, T., Doi, Y., Mizoguchi, H., Jin, S., Noda, M., Sonobe, Y., Takeuchi, H., & Suzumura, A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.011 · Cited by 159 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Smith, J. K. (2020) · Life · doi:10.3390/life10090207 · Cited by 52 · see citing works
“IL-34 produced by osteoblasts recognizes the receptor for M-CSF (C-Fms) on osteoclast progenitors, thereby promoting osteoclastogenesis [38].”
Background
- Authors
- Guillonneau, C., Bézie, S., & Anegon, I.
- Affiliations
- Inserm (FR)
- Corresponding author
- Guillonneau, Carole
- ORCID
- Guillonneau, Carole
- Venue
- Cellular and Molecular Life Sciences
- Published
- 2017-03-03
- Volume
- 74
- Issue
- 14
- Pages
- 2569-2586
- ISSN
- 1420-682X (ISSN-L)
- 1420-9071
- PMC
- PMC11107603
- OpenAlex
- W2593594734
- Cited by
- 112
- References
- 3
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 9 · 2023: 13 · 2022: 15 · 2021: 15 · 2020: 10 · 2019: 18 · 2018: 14 · 2017: 6
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cellular and Molecular Life Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-IBHU-0005, ANR-11-LABX-0016)
- Topics
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Keywords
- IL-34, immune regulation, CSF-1 receptor, syndecan-1, macrophage differentiation, dendritic cells, Foxp3+ regulatory T cells, transplantation tolerance, cytokine therapy
- MeSH terms
- Animals, Clinical Trials as Topic, Humans, Interleukins, Models, Biological, Macrophage Colony-Stimulating Factor, Immunomodulation, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review